| Year |
Citation |
Score |
| 2023 |
Ginebaugh SP, Badawi Y, Laghaei R, Mersky G, Wallace CJ, Tarr TB, Kaufhold C, Reddel S, Meriney SD. Simulations of active zone structure and function at mammalian NMJs predict that loss of calcium channels alone is not sufficient to replicate LEMS effects. Journal of Neurophysiology. PMID 37073966 DOI: 10.1152/jn.00404.2022 |
0.733 |
|
| 2022 |
Sarkar D, Kang J, Wassie AT, Schroeder ME, Peng Z, Tarr TB, Tang AH, Niederst ED, Young JZ, Su H, Park D, Yin P, Tsai LH, Blanpied TA, Boyden ES. Revealing nanostructures in brain tissue via protein decrowding by iterative expansion microscopy. Nature Biomedical Engineering. PMID 36038771 DOI: 10.1038/s41551-022-00912-3 |
0.713 |
|
| 2022 |
Ginebaugh SP, Badawi Y, Tarr TB, Meriney SD. Neuromuscular Active Zone Structure and Function in Healthy and Lambert-Eaton Myasthenic Syndrome States. Biomolecules. 12. PMID 35740866 DOI: 10.3390/biom12060740 |
0.736 |
|
| 2020 |
Held RG, Liu C, Ma K, Ramsey AM, Tarr TB, De Nola G, Wang SSH, Wang J, van den Maagdenberg AMJM, Schneider T, Sun J, Blanpied TA, Kaeser PS. Synapse and Active Zone Assembly in the Absence of Presynaptic Ca Channels and Ca Entry. Neuron. PMID 32616470 DOI: 10.1016/J.Neuron.2020.05.032 |
0.682 |
|
| 2017 |
Laghaei R, Ma J, Tarr T, Homan AE, Kelly L, Tilvawala M, Vuocolo B, Rajasekaran H, Meriney SD, Dittrich M. Transmitter release site organization can predict synaptic function at the neuromuscular junction. Journal of Neurophysiology. PMID 29357458 DOI: 10.1152/jn.00168.2017 |
0.702 |
|
| 2017 |
Meriney SD, Tarr TB, Ojala KS, Wu M, Li Y, Lacomis D, Garcia-Ocaña A, Liang M, Valdomir G, Wipf P. Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads. Annals of the New York Academy of Sciences. PMID 29125190 DOI: 10.1111/Nyas.13512 |
0.743 |
|
| 2014 |
Tarr TB, Wipf P, Meriney SD. Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome. Molecular Neurobiology. PMID 25195700 DOI: 10.1007/S12035-014-8887-2 |
0.702 |
|
| 2014 |
Tarr TB, Lacomis D, Reddel SW, Liang M, Valdomir G, Frasso M, Wipf P, Meriney SD. Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist. The Journal of Physiology. 592: 3687-96. PMID 25015919 DOI: 10.1113/Jphysiol.2014.276493 |
0.745 |
|
| 2013 |
Tarr TB, Malick W, Liang M, Valdomir G, Frasso M, Lacomis D, Reddel SW, Garcia-Ocano A, Wipf P, Meriney SD. Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 33: 10559-67. PMID 23785168 DOI: 10.1523/Jneurosci.4629-12.2013 |
0.739 |
|
| 2013 |
Tarr TB, Dittrich M, Meriney SD. Are unreliable release mechanisms conserved from NMJ to CNS? Trends in Neurosciences. 36: 14-22. PMID 23102681 DOI: 10.1016/j.tins.2012.09.009 |
0.737 |
|
| 2012 |
Liang M, Tarr TB, Bravo-Altamirano K, Valdomir G, Rensch G, Swanson L, DeStefino NR, Mazzarisi CM, Olszewski RA, Wilson GM, Meriney SD, Wipf P. Synthesis and biological evaluation of a selective N- and p/q-type calcium channel agonist. Acs Medicinal Chemistry Letters. 3: 985-90. PMID 24936234 DOI: 10.1021/Ml3002083 |
0.707 |
|
| 2012 |
Tarr TB, Valdomir G, Liang M, Wipf P, Meriney SD. New calcium channel agonists as potential therapeutics in Lambert-Eaton myasthenic syndrome and other neuromuscular diseases. Annals of the New York Academy of Sciences. 1275: 85-91. PMID 23278582 DOI: 10.1111/Nyas.12001 |
0.729 |
|
| Show low-probability matches. |